117 related articles for article (PubMed ID: 26394902)
1. Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen.
Fabbiani M; Zaccarelli M; Latini A; Sterrantino G; D'Ettorre G; Grima P; Mondi A; Rossetti B; Borchi B; Giuliani M; Antinori A; De Luca A; Di Giambenedetto S
HIV Med; 2016 May; 17(5):385-9. PubMed ID: 26394902
[TBL] [Abstract][Full Text] [Related]
2. Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients.
Fabbiani M; Zaccarelli M; Grima P; Prosperi M; Fanti I; Colafigli M; D'Avino A; Mondi A; Borghetti A; Fantoni M; Cauda R; Di Giambenedetto S
BMC Infect Dis; 2014 Jan; 14():26. PubMed ID: 24418191
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
[TBL] [Abstract][Full Text] [Related]
5. Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries.
Cohen J; Beaubrun A; Bashyal R; Huang A; Li J; Baser O
AIDS Res Ther; 2020 Apr; 17(1):12. PubMed ID: 32238169
[TBL] [Abstract][Full Text] [Related]
6. Durability of single tablet regimen for patients with HIV infection in Southern Taiwan: data from a real-world setting.
Chang HM; Chou CH; Tsai HC
BMC Infect Dis; 2022 Jan; 22(1):2. PubMed ID: 34983388
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
[TBL] [Abstract][Full Text] [Related]
8. Comparison of adherence to generic multi-tablet regimens vs. brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients.
Rwagitinywa J; Lapeyre-Mestre M; Bourrel R; Montastruc JL; Sommet A
Fundam Clin Pharmacol; 2018 Aug; 32(4):450-458. PubMed ID: 29505661
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.
Leutscher PD; Stecher C; Storgaard M; Larsen CS
Scand J Infect Dis; 2013 Aug; 45(8):645-51. PubMed ID: 23427878
[TBL] [Abstract][Full Text] [Related]
10. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy.
Blanco JL; Montaner JS; Marconi VC; Santoro MM; Campos-Loza AE; Shafer RW; Miller MD; Paredes R; Harrigan R; Nguyen ML; Perno CF; Gonzalez-Hernandez LA; Gatell JM
AIDS; 2014 Nov; 28(17):2531-9. PubMed ID: 25574957
[TBL] [Abstract][Full Text] [Related]
11. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.
van Lunzen J; Antinori A; Cohen CJ; Arribas JR; Wohl DA; Rieger A; Rachlis A; Bloch M; Segal-Maurer S; Garner W; Porter D; Bosse M; Piontkowsky D; Chuck SK; De-Oertel S
AIDS; 2016 Jan; 30(2):251-9. PubMed ID: 26684822
[TBL] [Abstract][Full Text] [Related]
12. Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database.
Raffi F; Yazdanpanah Y; Fagnani F; Laurendeau C; Lafuma A; Gourmelen J
J Antimicrob Chemother; 2015 Jul; 70(7):2121-8. PubMed ID: 25904729
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
14. Switching from a two-tablet regimen of tenofovir/emtricitabine and efavirenz to a one-tablet regimen may affect patients' perceptions and drug management.
Rotzinger A; Locatelli I; Bugnon O; Fayet Mello A; Parienti JJ; Cavassini M; Schneider MP
HIV Med; 2016 May; 17(5):390-6. PubMed ID: 26688004
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of central nervous system symptoms among HIV-1 infected efavirenz users: analysis of patient electronic medical record data.
Rosenblatt L; Broder MS; Bentley TGK; Chang E; Reddy SR; Papoyan E; Myers J
AIDS Care; 2017 Aug; 29(8):1067-1073. PubMed ID: 28147708
[TBL] [Abstract][Full Text] [Related]
16. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with HIV viral load "blips" and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study.
Farmer A; Wang X; Ganesan A; Deiss RG; Agan BK; O'Bryan TA; Akers K; Okulicz JF
AIDS Res Ther; 2016; 13():16. PubMed ID: 27006682
[TBL] [Abstract][Full Text] [Related]
18. The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens.
Casado JL; Marín A; Romero V; Bañón S; Moreno A; Perez-Elías MJ; Moreno S; Rodriguez-Sagrado MA
HIV Med; 2016 Jan; 17(1):46-55. PubMed ID: 26149493
[TBL] [Abstract][Full Text] [Related]
19. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases.
Allavena C; Le Moal G; Michau C; Chiffoleau A; Raffi F
Antivir Ther; 2006; 11(2):263-5. PubMed ID: 16640107
[TBL] [Abstract][Full Text] [Related]
20. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy.
Scott Sutton S; Magagnoli J; Hardin JW
Pharmacotherapy; 2016 Apr; 36(4):385-401. PubMed ID: 26923931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
